Literature DB >> 30302723

Tumor Type-Agnostic Treatment and the Future of Cancer Therapy.

Luis E Raez1, Edgardo S Santos2.   

Abstract

Mesh：

Year:  2018        PMID： 30302723     DOI： 10.1007/s11523-018-0593-y

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  28 in total

1.  Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.

Authors:  Liqiang Xi; Evgeny Arons; Winnifred Navarro; Katherine R Calvo; Maryalice Stetler-Stevenson; Mark Raffeld; Robert J Kreitman
Journal:  Blood       Date:  2011-12-30       Impact factor: 22.113

2.  Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.

Authors:  Reinhard Dummer; Paolo A Ascierto; Helen J Gogas; Ana Arance; Mario Mandala; Gabriella Liszkay; Claus Garbe; Dirk Schadendorf; Ivana Krajsova; Ralf Gutzmer; Vanna Chiarion-Sileni; Caroline Dutriaux; Jan Willem B de Groot; Naoya Yamazaki; Carmen Loquai; Laure A Moutouh-de Parseval; Michael D Pickard; Victor Sandor; Caroline Robert; Keith T Flaherty
Journal:  Lancet Oncol       Date:  2018-03-21       Impact factor: 41.316

3.  Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Authors:  Scott N Gettinger; Leora Horn; Leena Gandhi; David R Spigel; Scott J Antonia; Naiyer A Rizvi; John D Powderly; Rebecca S Heist; Richard D Carvajal; David M Jackman; Lecia V Sequist; David C Smith; Philip Leming; David P Carbone; Mary C Pinder-Schenck; Suzanne L Topalian; F Stephen Hodi; Jeffrey A Sosman; Mario Sznol; David F McDermott; Drew M Pardoll; Vindira Sankar; Christoph M Ahlers; Mark Salvati; Jon M Wigginton; Matthew D Hellmann; Georgia D Kollia; Ashok K Gupta; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2015-04-20       Impact factor: 44.544

4.  Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers.

Authors:  Kathleen M Murphy; Shengle Zhang; Tanya Geiger; Michael J Hafez; Jeff Bacher; Karin D Berg; James R Eshleman
Journal:  J Mol Diagn       Date:  2006-07       Impact factor: 5.568

5.  BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.

Authors:  Rachel N Grisham; Gopa Iyer; Karuna Garg; Deborah Delair; David M Hyman; Qin Zhou; Alexia Iasonos; Michael F Berger; Fanny Dao; David R Spriggs; Douglas A Levine; Carol Aghajanian; David B Solit
Journal:  Cancer       Date:  2012-08-28       Impact factor: 6.860

Review 6.  TRK Inhibition: A New Tumor-Agnostic Treatment Strategy.

Authors:  Shivaani Kummar; Ulrik N Lassen
Journal:  Target Oncol       Date:  2018-10       Impact factor: 4.493

7.  Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Authors:  Arnaud D Roth; Sabine Tejpar; Mauro Delorenzi; Pu Yan; Roberto Fiocca; Dirk Klingbiel; Daniel Dietrich; Bart Biesmans; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Laura Cisar; Roberto Labianca; David Cunningham; Eric Van Cutsem; Fred Bosman
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

8.  The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.

Authors:  Elena Ardini; Roberta Bosotti; Andrea Lombardi Borgia; Cristina De Ponti; Alessio Somaschini; Rosaria Cammarota; Nadia Amboldi; Laura Raddrizzani; Andrea Milani; Paola Magnaghi; Dario Ballinari; Daniele Casero; Fabio Gasparri; Patrizia Banfi; Nilla Avanzi; Maria B Saccardo; Rachele Alzani; Tiziano Bandiera; Eduard Felder; Daniele Donati; Enrico Pesenti; Andrea Sartore-Bianchi; Marcello Gambacorta; Marco A Pierotti; Salvatore Siena; Silvio Veronese; Arturo Galvani; Antonella Isacchi
Journal:  Mol Oncol       Date:  2014-06-12       Impact factor: 6.603

Review 9.  Trk receptor expression and inhibition in neuroblastomas.

Authors:  Garrett M Brodeur; Jane E Minturn; Ruth Ho; Anisha M Simpson; Radhika Iyer; Carly R Varela; Jennifer E Light; Venkatadri Kolla; Audrey E Evans
Journal:  Clin Cancer Res       Date:  2009-05-05       Impact factor: 12.531

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.